Speakers

Anthony L. Back, MD

Professor of Oncology

University of Washington, Seattle

Dr. Back presents findings from a study of anxiety and depression in patients with metastatic and incurable cancers using a group dosage session protocol within a retreat environment.

Kevin Balktick

Founder + Director

Horizons Media, Inc.

Ritu S. Baral

Managing Director & Sr. Biotechnology Analyst

TD Cowen

Myriam Barthes

CEO and Co-Founder

Journey Clinical

Myriam Barthes explains how independent therapists can offer psychedelic-assisted psychotherapy to their patients, with medical support, insurance coverage, education and community.

Al Bugazia, MD

Deputy Director, Proactive Health

ARPA-H

Dr. Al Bugazia joined ARPA-H in May 2026 and is an internal medicine and critical care–trained physician with more than a decade of experience as an intensivist, educator, and adjunct associate professor at the University of Wisconsin School of Medicine. He completed his critical care fellowship at Cleveland Clinic, where he served as Chief Fellow, before going on to care for critically ill patients and train the next generation of physicians.

A.J. Cannon, MD

Medical Director, Neuroscience Clinical Development

AbbVie

Dr. Cannon, a Medical Director managing a CNS portfolio at AbbVie, one of the world’s largest pharmaceutical companies, brings a critical industry perspective to the discussion of psychedelic drug development.

Lori Englebert

Chief Commercial Officer

Compass Pathways

Gisele Fernandes-Osterhold, LMFT

Director of Psychedelic Facilitation, TrPR Program

University of California San Francisco (UCSF)

Gisele Fernandes-Osterhold presents recent psilocybin study data for Parkinson’s, chronic pain, and others while considering meaning-making, quality of life, and psychological aspects of psychedelic therapy.

Manesh Girn, PhD

Postdoctoral Neuroscientist

University of California, San Francisco

Jazz Glastra

Senior Director

BrainFutures

Jazz Glastra illuminates the reality and complexity of a post-approval world, where numerous regulatory and insurance challenges may still stand in between approvals and appointments.

Guy Goodwin, MD

Chief Medical Officer

Compass Pathways

Dr. Goodwin, one of the most cited researchers in psychiatry, presents the findings of the largest psilocybin treatment trial in the world, and the questions that will inform the next generation of research.

Andrew Gradison, JD

Senior Advisor, Veterans Health Administration

U.S. Department of Veterans Affairs

Harry Grammer, PhD

Founder

New Earth

Dr. Grammer, who has devoted his life to reforming the juvenile justice system, shares his experiences bringing psychedelic healing to recently-released youth communities in Los Angeles.

Josh Hardman

Founder & Editor

Psychedelic Alpha

Rikki Harris

CEO

TN Voices

Rikki Harris shares the story of how a community coalition realized a landmark law to accelerate the research into ibogaine therapy in Tennessee.

Julie Holland, MD

Psychiatrist

Private practice, New York City

Bryan Hubbard

CEO

Americans for Ibogaine

In his return to the Horizons stage, Bryan Hubbard tells how ibogaine went from obscurity to the Oval Office, and how state and federal governments can accelerate the next wave of research.

Edny Inui, PhD, MBA

Partner

Palo Santo

Daniel R. Karlin, MD, MA

Chief Medical Officer

Definium Therapeutics

Bia Labate, PhD

Executive Director

Chacruna Institute

Amy Lehrner, PhD

Assistant Professor of Psychiatry

Icahn School of Medicine at Mount Sinai

Alberto “Nachi” López Pérez

Board Member and Huachuma Conservation Center Director

Colectivo Huachuma

Don Alberto “Nachi” Lopez is a respected elder of the Indigenous Andean community of San Pedro de Casta in Peru. For 50 years, he has been a curandero (healer) and naturista (herbalist) who maintains a successful traditional medicine practice. He is a member of the Board of Directors of Huachuma Collective, an Indigenous-led nonprofit organization in Peru that conserves the San Pedro cactus, its culture and traditions. Don Nachi is Director of the first Huachuma Conservation Center in Peru, a collaborative project between Huachuma Collective and the Indigenous community of San Pedro de Casta.

Kate Reynolds, MPH

Director of Research

Rocky Mountain Poison & Drug Safety

Kate Reynolds presents a major representative survey of the attitudes and use patterns of Americans towards psychedelics. This study sets a new standard for granularity and scale and reveals novel trends and insights.

Kim Roddy, MBA

Chief Operating Officer, Co-Founder

Sunstone Therapies

Dalibor Sames

Professor of Chemistry

Columbia University

William M. Sauve, MD

Chief Medical Officer

Osmind

Tanya Brara Shah

Strategic Advisor

Psychedelic Mental Health Access Alliance

Tanya Brara Shah brings over 20 years of diverse experience in the private, public, and non-profit healthcare sectors. With a focus on bridging research, policy, and practice, she is dedicated to advancing integrated, innovative care models for complex populations.

Laurel Anne Sugden

Co-founder and Executive Director

Collective Huachuma

Connor Williams

Senior Research Analyst

RTW Investments

Rachel Yehuda, PhD

Chemers Neustein Family Professor of Trauma and Resilience

Icahn School of Medicine at Mount Sinai